Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL) Carlo-Stella, C., Ansell, S., Zinzani, P., Radford, J., Maddocks, K., Pinto, A., Collins, G. P., Bachanova, V., Bartlett, N., Bence-Bruckler, I., Hamadani, M., Kline, J., Mayer, J., Savage, K. J., Advani, R., Caimi, P., Casasnovas, R., Feldman, T., Hess, B., Bastos-Oreiro, M., Iyengar, S., Eisen, S., Negievich, Y., Wang, L., Wuerthner, J., Herrera, A. F. CIG MEDIA GROUP, LP. 2022: S347

View details for Web of Science ID 000897948100357